Clinical Trial

Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

Study acronym: NARNIA
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2023 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-14.
Status change: Not Yet Recruiting → Recruiting 2023-03-16
Trial Details
NCT Number NCT05732051
Lead Sponsor University Hospital, Akershus
Collaborators: ChromaDex, Inc., Norwegian Cancer Society, Norwegian Breast Cancer Association, Helse Sor-Ost
Conditions Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity, Heart Failure
Enrollment 60 participants
Start Date 2023-03-16
Primary Completion 2025-08-01 (estimated)
Study Completion 2035-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-03-17